Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.

Pathology oncology research : POR - 1 Jan 2022

Boniface Christopher T, Spellman Paul T

Abstract excerpt

Collection and analysis of circulating tumor DNA (ctDNA) is one of the few methods of liquid biopsy that measures generalizable and tumor specific molecules, and is one of the most promising approaches in assessing the effectiveness of cancer care. Clinical assays that utilize ctDNA are commercially available for the identification of actionable mutations prior to treatment and to assess minimal residual disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Docetaxel

Share to Liquid Biopsy

Share to Mutation

Share to Neoplasm, Residual

Source

Open in PubMed Open full text

Identifiers

PMID: 35665409
DOI: 10.3389/pore.2022.1610103
PMCID: PMC9160182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.PMID 35665409Read ↗

Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity Read ↗

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevanceSemantic proximity Read ↗

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.Semantic proximity Read ↗

Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Semantic proximity Read ↗

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.Semantic proximity Read ↗

Circulating-tumor DNA as an early detection and diagnostic tool.Semantic proximity Read ↗

Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseSemantic proximity Read ↗

Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.Semantic proximity Read ↗

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With ImmunotherapySemantic proximity Read ↗

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.